Table 1 Patient characteristics.

From: TCF1⁺ hepatitis C virus-specific CD8⁺ T cells are maintained after cessation of chronic antigen stimulation

Pt	D	Cohort	Treatment	Outcome	gt	NS3 ₁₀₇₃	NS3 ₁₄₀₆	NS5 ₂₅₉₄	VL	Age	Sex	CIR
1	cHCV	DAA	Ledipasvir/Sofosbuvir 8 wk	SVR	1a		------V---		0.15	47	f	no
2	cHCV	DAA	Ledipasvir/Sofosbuvir 12 wk	SVR	1a	---------			0.26	60	m	no
3	cHCV	DAA	Ledipasvir/Sofosbuvir 12 wk	SVR	1a	---------	----------		1.06	52	m	no
4	cHCV	DAA	Ledipasvir/Sofosbuvir 12 wk	SVR	1a		------V---		3.20	66	f	no
5	cHCV	DAA	Ledipasvir/Sofosbuvir 12 wk	SVR	1a	---------		----------	0.63	59	f	no
6	cHCV	DAA	Ledipasvir/Sofosbuvir 12 wk	SVR	1a		----------	----------	0.68	64	f	no
7	cHCV	DAA	Ledipasvir/Sofosbuvir 12 wk	SVR	1a	---------		----------	2.96	50	m	no
8	cHCV	DAA	Ledipasvir/Sofosbuvir 12 wk	SVR	1a	---------			ND	49	m	no
9	cHCV	DAA	Ledipasvir/Sofosbuvir 12 wk	SVR	1a	---------		----------	15.0	58	m	no
10	cHCV	DAA	Ledipasvir/Sofosbuvir 12 wk	SVR	1a	---------			0.29	59	m	no
11	cHCV	DAA	Ledipasvir/Sofosbuvir 12 wk	SVR	1a	---------			1.03	47	m	no
12	cHCV	DAA	Ledipasvir/Sofosbuvir/Ribavirin 12 wk	SVR	1a		------V---		0.04	73	f	no
13	cHCV	DAA	Ledipasvir/Sofosbuvir/Ribavirin 12 wk; untreated after relapse	RELAPSE	1a	---------			ND	62	m	yes
14	cHCV	DAA	Ledipasvir/Sofosbuvir 8 wk	SVR	1b	-I-------			0.70	49	m	no
15	cHCV	DAA	Ledipasvir/Sofosbuvir 8 wk	SVR	1b	---------			0.30	60	f	no
16	cHCV	DAA	Ledipasvir/Sofosbuvir 12 wk	SVR	1b	---------			5.30	78	f	no
17	cHCV	DAA	Ledipasvir/Sofosbuvir 12 wk	SVR	1b	---------			1.00	63	f	no
18	cHCV	DAA	Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir 12 wk	SVR	1b	-I-------			1.23	29	m	no
19	cHCV	DAA	Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir/Ribavirin 12 wk	SVR	1b	---------			0.04	66	f	no
20	cHCV	DAA	Ledipasvir/Sofosbuvir/Ribavirin 12 wk	SVR	1b	-I-------			0.61	58	f	no
21	cHCV	untreated	-	-	1a	---------			1.36	41	m	no
22	cHCV	untreated	-	-	1a	---------			4.59	51	m	no
23	cHCV	untreated	-	-	1a		----------		0.41	55	f	no
1	cHCV	ESC	Ledipasvir/Sofosbuvir 8 wk	SVR	1a	--------A			0.15	47	f	no
4	cHCV	ESC	Ledipasvir/Sofosbuvir 12 wk	SVR	1a	--------A			3.2	66	f	no
12	cHCV	ESC	Ledipasvir/Sofosbuvir/Ribavirin12 wk	SVR	1a	--------A			0.04	73	f	no
24	cHCV	ESC	Ledipasvir/Sofosbuvir 12 wk	SVR	1b	--S------			2.46	56	f	no
25	cHCV	ESC	-	SVR	1b	-------SA			0.04	57	m	no

Pt	D	Cohort	Approx. time after primary HCV infection	Age	Sex	CIR
26	SpR	SpR	22 years	43	m	no
27	SpR	SpR	unknown	39	f	no
28	SpR	SpR	unknown	25	m	no
29	SpR	SpR	unknown	67	f	no
30	SpR	SpR	unknown	38	f	no
31	SpR	SpR	unknown	23	m	no
32	SpR	SpR	unknown	54	m	no
33	SpR	SpR	unknown	57	f	no
34	SpR	SpR	unknown	42	m	no
35	SpR	SpR	12 years	39	f	no
36	SpR	SpR	19 years	37	m	no
37	SpR	SpR	unknown	38	m	no
38	SpR	SpR	unknown	60	f	no
39	SpR	SpR	unknown	54	f	no
40	SpR	SpR	13 years	33	m	no

CIR, cirrhosis; D, diagnosis; f, female; gt, HCV genotype; m, male; ND, not defined; Pt, patient; SVR, sustained virological response; VL, baseline viral load (IU ml⁻¹ × 10⁶); wk, week.
Patient characteristics are depicted. Listed are chronically HCV-infected patients (cHCV) with and without DAA treatment (DAA or untreated) and spontaneous HCV resolvers (SpR). In column NS3₁₀₇₃, NS3₁₄₀₆ and NS5₂₅₉₄ the viral sequence for each analysed CD8⁺ T-cell epitope during chronic HCV infection is shown: (-) indicates a sequence position that corresponds to wild type viral sequence, capital letters show amino acid substitutions varying from wild type sequence. Patients with analysed HCV epitope-specific CD8⁺ T cells that do not recognize viral antigen due to viral escape mutation in their corresponding epitope are listed in ESC (viral escape) cohort. If known, the approximate time after primary HCV inection of a SpR patient is indicated.

Back to article page

Table 1 Patient characteristics.

Search

Quick links